UB Paderborn / Katalog / Suche / in CDI

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Cancer, 2012-05, Vol.118 (10), p.2594-2602

2012

Link zum Volltext

Verfügbarkeit prüfen

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Clinical cancer research, 2008-02, Vol.14 (3), p.797-803

2008

Link zum Volltext

Verfügbarkeit prüfen

Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors

Clinical immunology (Orlando, Fla.), 2019-04, Vol.201, p.48-54

2019

Link zum Volltext

Verfügbarkeit prüfen

Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer

Clinical immunology (Orlando, Fla.), 2021-04, Vol.225, p.108679-108679, Article 108679

2021

Link zum Volltext

Verfügbarkeit prüfen

The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Clinical cancer research, 2009-04, Vol.15 (8), p.2895-2904

2009

Link zum Volltext

Verfügbarkeit prüfen

Results of the first phase 1 clinical trial of the HER‐2/neu peptide (GP2) vaccine in disease‐free breast cancer patients

Cancer, 2010-01, Vol.116 (2), p.292-301

2010

Link zum Volltext

Verfügbarkeit prüfen

Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study

Journal of infusion nursing, 2021-11, Vol.44 (6), p.315

2021

Link zum Volltext

Verfügbarkeit prüfen

The E75 HER2/neu peptide vaccine

Cancer Immunology, Immunotherapy, 2008-10, Vol.57 (10), p.1511-1521

2008

Link zum Volltext

Verfügbarkeit prüfen

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04

Cancer, 2010-01, Vol.116 (2), p.292-301

2010

Link zum Volltext

Verfügbarkeit prüfen

Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer

Clinical cancer research, 2020-06, Vol.26 (11), p.2515-2523

2020

Link zum Volltext

Verfügbarkeit prüfen

The GP2 peptide: A HER2/neu-based breast cancer vaccine

Journal of surgical oncology, 2012-04, Vol.105 (5), p.452-458

2012

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/ neu -Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

Journal of the American College of Surgeons, 2010-02, Vol.210 (2), p.140-147

2010

Link zum Volltext

Verfügbarkeit prüfen

Use of Booster Inoculations to Sustain the Clinical Effect of an Adjuvant Breast Cancer Vaccine: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Cancer, 2011-02, Vol.117 (3), p.463-471

2011

Link zum Volltext

Verfügbarkeit prüfen

Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?

Expert review of vaccines, 2010-05, Vol.9 (5), p.519-525

2010

Link zum Volltext

Verfügbarkeit prüfen

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Cancer, 2008-10, Vol.113 (7), p.1666-1675

2008

Link zum Volltext

Verfügbarkeit prüfen

Circulating regulatory T cells (CD4+ CD25+ FOXP3+ ) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/ neu (AE37) peptide

Vaccine, 2010-11, Vol.28 (47), p.7476-7482

2010

Link zum Volltext

Verfügbarkeit prüfen

AE37: a novel T-cell-eliciting vaccine for breast cancer

Expert opinion on biological therapy, 2011-11, Vol.11 (11), p.1543-1550

2011

Link zum Volltext

Verfügbarkeit prüfen

Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine

Cancer, 2011-02, Vol.117 (3), p.463-471

2011

Link zum Volltext

Verfügbarkeit prüfen

Longterm Followup Assessment of a HER2/ neu Peptide (E75) Vaccine for Prevention of Recurrence in High-Risk Prostate Cancer Patients

Journal of the American College of Surgeons, 2009-02, Vol.208 (2), p.193-201

2009

Link zum Volltext

Verfügbarkeit prüfen

Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines

Expert review of vaccines, 2011-02, Vol.10 (2), p.201-210

2011

Link zum Volltext

Verfügbarkeit prüfen

CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37)

Expert opinion on biological therapy, 2009-01, Vol.9 (1), p.71-78

2009

Link zum Volltext

Verfügbarkeit prüfen

CD4+ T cells in antitumor immunity: utility of an Ii-Key HER2/neu hybrid peptide vaccine (AE37)

Expert opinion on biological therapy, 2009-01, Vol.9 (1), p.71-78

2009

Link zum Volltext

Verfügbarkeit prüfen

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Cancer Immunology, Immunotherapy, 2008-12, Vol.57 (12), p.1817-1825

2008

Link zum Volltext

Verfügbarkeit prüfen

Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study

Annals of surgical oncology, 2007-12, Vol.14 (12), p.3359-3368

2007

Link zum Volltext

Verfügbarkeit prüfen

Folate receptor α: A storied past and promising future in immunotherapy

Human vaccines, 2011-02, Vol.7 (2), p.183-190

2011

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors

Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer

The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Results of the first phase 1 clinical trial of the HER‐2/neu peptide (GP2) vaccine in disease‐free breast cancer patients

Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study

The E75 HER2/neu peptide vaccine

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04

Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer

The GP2 peptide: A HER2/neu-based breast cancer vaccine

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/ neu -Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

Use of Booster Inoculations to Sustain the Clinical Effect of an Adjuvant Breast Cancer Vaccine: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Circulating regulatory T cells (CD4+ CD25+ FOXP3+ ) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/ neu (AE37) peptide

AE37: a novel T-cell-eliciting vaccine for breast cancer

Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine

Longterm Followup Assessment of a HER2/ neu Peptide (E75) Vaccine for Prevention of Recurrence in High-Risk Prostate Cancer Patients

Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines

CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37)

CD4+ T cells in antitumor immunity: utility of an Ii-Key HER2/neu hybrid peptide vaccine (AE37)

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study

Folate receptor α: A storied past and promising future in immunotherapy

Suchergebnisse filtern